Assistant Professor, Harvard Medical School, Boston MA Director, Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center, Boston MA Associate Member, Broad Institute
The chromatin regulators CBP and p300 maintain gene expression programs through lysine acetylation of chromatin and transcriptional regulators and by scaffolding functions mediated by several protein-protein interaction domains. We have developed a chemical degrader of p300/CBP, dCBP-1, using in silico modeling and cellular activity assays including capillary-based immunodetection assays (ProteinSimple, WES). We have found that dCBP-1 is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drive MYC oncogene expression. As an efficient degrader of this unique class of chromatin regulators, dCBP-1 will be a useful tool for understanding p300/CBP activity at enhancers in both normal and diseased cells.
Webinars will be available for unlimited on-demand viewing after live event.
Long-read sequencing is transforming the landscape of genomic research, offering exceptional resolution and accuracy in the analysis of complex genetic structures. From research in genetic a...
Biosafety cabinets (BSCs) are a cornerstone of modern laboratory safety, yet many users lack a clear understanding of how they work, how to use them properly, and how to distinguish between...
Laboratories are under growing pressure to meet both stringent safety standards and ambitious sustainability goals—often with limited resources. This webinar, hosted by Erlab, a global...
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to iso...
The analysis of protein behavior and protein interactions is central in drug research. In this web seminar, we will show you how the automation of protein purification and downstream thermal...
This presentation explores the scientific rationale, preclinical validation, and early clinical translation of STAR-LLD—a novel, continuous low-dose percutaneous lenalidomide delivery...
Loading Comments...
Please update your information
Certificate of Participation
Thank you for choosing Labroots. Please note that a Certificate of Participation does NOT count towards Continuing Education Credits.